We also demonstrated that ZEB1 upregulation was observed in additional NSCLC cell lines and human samples with EMT-related EGFR-TKI resistance, suggesting that ZEB1 is a possible target to overcome this kind of resistance in clinical lung cancer. This evidence concerns the gene EGFR and non-small cell lung carcinoma.